Full Press Release Details
Revenues increased to €37.7 M (from €31.6 M on pro forma basis, +19%)
Net loss reduced to €7.3 M (from €7.9 M, -7 %)
Cash burn reduced to €8.6 M (from €21.9 M, -61%)
BioFocus DPI external revenues growth of 11%
BioFocus DPI operating profit of €3.4 M (from loss of €1.2 M)
Cash position of €18.7 M on 30 June 2009
Confirmation guidance of €100 M full year revenues and €20 M year end cash position
Positive results of clinical Phase I study with GLPG0259 in rheumatoid arthritis
Ongoing clinical Phase I study with GLPG0187 in bone metastasis
Announced two alliances with Merck & Co. for a potential value of €490 M plus royalties
Achieved milestones in all three bone & joint alliances